Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Journey Medical Corp (DERM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: DERM (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.8
1 Year Target Price $11.8
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 67.98% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 187.06M USD | Price to earnings Ratio - | 1Y Target Price 11.8 |
Price to earnings Ratio - | 1Y Target Price 11.8 | ||
Volume (30-day avg) 4 | Beta 0.81 | 52 Weeks Range 3.54 - 8.90 | Updated Date 09/16/2025 |
52 Weeks Range 3.54 - 8.90 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.49% | Operating Margin (TTM) -19.16% |
Management Effectiveness
Return on Assets (TTM) -5.86% | Return on Equity (TTM) -57.22% |
Valuation
Trailing PE - | Forward PE 28.41 | Enterprise Value 192046990 | Price to Sales(TTM) 3.32 |
Enterprise Value 192046990 | Price to Sales(TTM) 3.32 | ||
Enterprise Value to Revenue 3.41 | Enterprise Value to EBITDA 17.72 | Shares Outstanding 20309800 | Shares Floating 12808299 |
Shares Outstanding 20309800 | Shares Floating 12808299 | ||
Percent Insiders 33.05 | Percent Institutions 32.59 |
Upturn AI SWOT
Journey Medical Corp
Company Overview
History and Background
Journey Medical Corporation, founded in 2014, focuses on acquiring, commercializing, and marketing pharmaceutical products, primarily for skin health.
Core Business Areas
- Dermatology Products: Acquisition, commercialization, and marketing of branded and generic prescription dermatology products for the treatment of various skin conditions.
Leadership and Structure
The leadership team consists of a CEO, CFO, and other key executives. The organizational structure is typical of a publicly traded pharmaceutical company, with departments for sales, marketing, research and development, and operations.
Top Products and Market Share
Key Offerings
- Qbrexza: A topical anticholinergic cloth for the treatment of primary axillary hyperhidrosis (excessive underarm sweating). Competitors include prescription antiperspirants and Botox injections. Market share data is not readily available.
- Luxamend: Emollient designed to relieve itching and dryness. Competitors include other emollient brands such as CeraVe and Eucerin. Market share data is not readily available.
Market Dynamics
Industry Overview
The dermatology market is characterized by high demand for both prescription and over-the-counter treatments for skin conditions. The market is driven by factors such as an aging population, increasing awareness of skin health, and the availability of new and innovative treatments.
Positioning
Journey Medical Corp focuses on acquiring and commercializing established dermatology products, targeting specific niches within the broader market. Their competitive advantage may lie in their ability to efficiently market and distribute acquired products.
Total Addressable Market (TAM)
The global dermatology market is expected to reach hundreds of billions of dollars. Journey Medical Corp. aims to capture a portion of this TAM through focused product acquisitions and commercialization.
Upturn SWOT Analysis
Strengths
- Portfolio of established dermatology products
- Experienced management team
- Focus on niche markets
- Strong sales and marketing capabilities
Weaknesses
- Reliance on acquired products
- Limited pipeline of new products
- High debt load (common in acquisition-focused companies)
- Small market capitalization
Opportunities
- Further acquisitions of dermatology products
- Expansion into new geographic markets
- Development of new formulations of existing products
- Partnerships with other pharmaceutical companies
Threats
- Competition from larger pharmaceutical companies
- Patent expirations
- Changes in healthcare regulations
- Economic downturn
Competitors and Market Share
Key Competitors
- VRX
- AGN
- LLY
Competitive Landscape
Journey Medical Corp competes with larger pharmaceutical companies with greater resources. Its advantage lies in its focus on specific dermatology niches and its ability to efficiently commercialize acquired assets. Its small size, however, makes it more vulnerable to market fluctuations and competition.
Major Acquisitions
Qbrexza
- Year: 2018
- Acquisition Price (USD millions): 150
- Strategic Rationale: Expanded the company's portfolio into the hyperhidrosis market.
Growth Trajectory and Initiatives
Historical Growth: Journey Medical Corp's historical growth is tied to its acquisition strategy and commercialization success of acquired assets.
Future Projections: Future growth depends on further acquisitions, successful commercialization, and management of debt.
Recent Initiatives: Recent strategic initiatives typically involve acquisitions, product launches, and partnerships. Check recent press releases and filings.
Summary
Journey Medical is a dermatology-focused company reliant on acquisitions for growth. While their product portfolio is established, they face competition from larger firms and carry debt from acquisitions. Key to their success is effective commercialization of new assets and managing financial liabilities. Future growth depends on continued acquisitions and managing expenses effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Investor Relations, Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor. Market share data is estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Journey Medical Corp
Exchange NASDAQ | Headquaters Scottsdale, AZ, United States | ||
IPO Launch date 2021-11-12 | Founder, President, CEO & Director Mr. Claude Maraoui | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 41 | Website https://journeymedicalcorp.com |
Full time employees 41 | Website https://journeymedicalcorp.com | ||
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.